CN111315783A - 用抗cd47和抗pd-l1治疗卵巢癌 - Google Patents

用抗cd47和抗pd-l1治疗卵巢癌 Download PDF

Info

Publication number
CN111315783A
CN111315783A CN201880071877.6A CN201880071877A CN111315783A CN 111315783 A CN111315783 A CN 111315783A CN 201880071877 A CN201880071877 A CN 201880071877A CN 111315783 A CN111315783 A CN 111315783A
Authority
CN
China
Prior art keywords
antibody
dose
subject
tumor
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880071877.6A
Other languages
English (en)
Chinese (zh)
Inventor
C·H·M·塔基莫托
M·P·晁
J-P·沃尔克梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blink Biomedical SAS
Original Assignee
Blink Biomedical SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blink Biomedical SAS filed Critical Blink Biomedical SAS
Publication of CN111315783A publication Critical patent/CN111315783A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880071877.6A 2017-10-18 2018-10-18 用抗cd47和抗pd-l1治疗卵巢癌 Pending CN111315783A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574073P 2017-10-18 2017-10-18
US62/574,073 2017-10-18
PCT/US2018/056442 WO2019079549A1 (en) 2017-10-18 2018-10-18 TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1

Publications (1)

Publication Number Publication Date
CN111315783A true CN111315783A (zh) 2020-06-19

Family

ID=64402251

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880071877.6A Pending CN111315783A (zh) 2017-10-18 2018-10-18 用抗cd47和抗pd-l1治疗卵巢癌

Country Status (12)

Country Link
US (1) US20210047416A1 (https=)
EP (2) EP4194470A1 (https=)
JP (3) JP7308190B2 (https=)
KR (1) KR20200070341A (https=)
CN (1) CN111315783A (https=)
AU (1) AU2018351007B2 (https=)
CA (1) CA3078430A1 (https=)
ES (1) ES2938652T3 (https=)
PL (1) PL3697819T3 (https=)
PT (1) PT3697819T (https=)
SI (1) SI3697819T1 (https=)
WO (1) WO2019079549A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747906A1 (en) 2016-01-11 2020-12-09 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
SI4177270T1 (sl) 2017-10-18 2024-10-30 Forty Seven, Inc. Terapija za raka jajčnikov na osnovi sredstva proti cd47
AU2019218271B2 (en) 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
US20220289848A1 (en) * 2019-05-17 2022-09-15 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
TWI855236B (zh) * 2020-02-28 2024-09-11 大陸商南京聖和藥業股份有限公司 抗cd47/抗pd-l1抗體及其應用
JP7627349B2 (ja) * 2021-01-08 2025-02-05 北京韓美薬品有限公司 抗ｐｄ－ｌ１／抗ｃｄ４７天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
WO2017117196A1 (en) * 2015-12-28 2017-07-06 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents
CN106999517A (zh) * 2014-10-07 2017-08-01 免疫医疗公司 抗体‑药物缀合物的新辅助剂用途
CN107207593A (zh) * 2014-12-09 2017-09-26 雷纳神经科学公司 抗pd‑1抗体及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
PT2970493T (pt) 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
BR112018005322A2 (pt) * 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999517A (zh) * 2014-10-07 2017-08-01 免疫医疗公司 抗体‑药物缀合物的新辅助剂用途
CN107207593A (zh) * 2014-12-09 2017-09-26 雷纳神经科学公司 抗pd‑1抗体及其使用方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
WO2017117196A1 (en) * 2015-12-28 2017-07-06 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER B. MORSE等: "Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer" *
R.M. BRIGHTWELL等: "The CD47 "don\'t eat me signal" is highly expressed in human ovarian cancer" *
RAN LIU等: "CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis" *
胡唯伟等: "肿瘤中PD-L1表达调控的分子机制研究进展" *

Also Published As

Publication number Publication date
WO2019079549A1 (en) 2019-04-25
EP3697819A1 (en) 2020-08-26
CA3078430A1 (en) 2019-04-25
EP3697819B1 (en) 2022-11-16
JP2023014162A (ja) 2023-01-26
AU2018351007A1 (en) 2020-05-21
AU2018351007B2 (en) 2024-05-16
PT3697819T (pt) 2023-02-20
JP7474827B2 (ja) 2024-04-25
KR20200070341A (ko) 2020-06-17
ES2938652T3 (es) 2023-04-13
EP4194470A1 (en) 2023-06-14
JP7308190B2 (ja) 2023-07-13
US20210047416A1 (en) 2021-02-18
PL3697819T3 (pl) 2023-03-06
SI3697819T1 (sl) 2023-01-31
JP2024024121A (ja) 2024-02-21
JP2021500336A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7474827B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
US20250066473A1 (en) Treatment of cancer with combinations of immunoregulatory agents
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
JP2021181482A (ja) 中枢神経系新生物における免疫チェックポイント阻害剤の使用
CN111247172A (zh) 基于抗cd47剂的卵巢癌疗法
HK40092424A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40032879A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40077720A (en) Treatment of cancer with combinations of immunoregulatory agents
JP2025537826A (ja) 抗ｓｉｒｐａ抗体についての効力予測バイオマーカー
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124B (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40043124A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032879

Country of ref document: HK

CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Delaware, USA

Applicant after: 47 LLC

Address before: California, USA

Applicant before: Forty-seven companies

Country or region before: U.S.A.

CB02 Change of applicant information